Appropriateness of direct oral anticoagulant dosing and its relation to drug levels in atrial fibrillation patients.
Direct-acting oral anticoagulants
Dose reduction
Drug levels
Monitoring
Real life
Journal
Journal of thrombosis and thrombolysis
ISSN: 1573-742X
Titre abrégé: J Thromb Thrombolysis
Pays: Netherlands
ID NLM: 9502018
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
pubmed:
29
1
2019
medline:
14
8
2019
entrez:
29
1
2019
Statut:
ppublish
Résumé
Direct oral anticoagulants (DOACs) are commonly administered at a level that is lower than that recommended by dose reduction criteria. This raises concern regarding the adequacy of anticoagulation achieved. To evaluate the relationship between inappropriate dosing and DOAC levels. Medical records of atrial fibrillation patients who underwent DOAC level testing during 2013-2017 were reviewed. The primary outcomes were drug levels under and above the expected steady-state range, and in the lowest and highest quartiles. Of 143 patients who underwent DOAC measurements, only 87 (60.8%) received the appropriate dose. Levels under the expected range and in the lowest quartile were found in 11.9% and 15.0% of patients treated with appropriate dosing compared to 21% and 41.5% of patients treated with inappropriately low dose. DOAC levels were above the expected range and in the highest quartile in 23.8% and 32.5% of patients treated with the appropriate dose compared to 7.1% and 9.4% treated with inappropriately low dose. In multivariate analysis, the administration of an appropriate DOAC dose was associated with a lower rate of DOAC in the lowest level (adjusted odds ratio [95% CI] 0.30 (0.12, 0.76), P = 0.011). On the other hand, appropriate dose was associated with drug levels in the highest quartile (odds ratio [95% CI] 3.77 (0.12, 0.76), P = 0.011). Treatment with inappropriately low DOAC dosing compared to appropriate dose is associated with lower DOAC levels. However, among those treated with appropriate dosing, a higher proportion had high DOAC levels above the expected range.
Identifiants
pubmed: 30689152
doi: 10.1007/s11239-019-01815-y
pii: 10.1007/s11239-019-01815-y
doi:
Substances chimiques
Anticoagulants
0
Types de publication
Clinical Trial
Journal Article
Langues
eng
Pagination
550-557Références
N Engl J Med. 2009 Sep 17;361(12):1139-51
pubmed: 19717844
Thromb Haemost. 2010 Jun;103(6):1116-27
pubmed: 20352166
Europace. 2010 Oct;12(10):1360-420
pubmed: 20876603
N Engl J Med. 2011 Sep 15;365(11):981-92
pubmed: 21870978
Kardiol Pol. 2012;70(1):102-3
pubmed: 22267443
Eur Heart J. 2016 Oct 7;37(38):2893-2962
pubmed: 27567408
S Afr Med J. 2016 Sep 08;106(10):1017-1020
pubmed: 27725023
J Thromb Thrombolysis. 2017 Feb;43(2):149-156
pubmed: 27757787
JAMA Cardiol. 2017 May 1;2(5):566-574
pubmed: 28355459
Europace. 2018 Oct 1;20(10):1577-1583
pubmed: 29186393
J Stroke Cerebrovasc Dis. 2018 Jun;27(6):1546-1551
pubmed: 29395644
J Thromb Haemost. 2018 May;16(5):842-848
pubmed: 29532628
Eur Heart J. 2018 Apr 21;39(16):1330-1393
pubmed: 29562325